Valuation Review and Technical Analysis of Antares Pharma Cmn (ATRS)

Lloyd Doyle
November 15, 2017

First Trust Advisors Lp decreased Bunge Limited (NYSE:BG) stake by 93,275 shares to 550,127 valued at $41.04M in 2017Q2. It also increased its holding in Adamas Pharmaceuticals Inc (NASDAQ:ADMS) by 294,000 shares in the quarter, for a total of 1.16 million shares, and has risen its stake in Spdr S&P 500 Etf Tr (Put) (SPY). Pinnacle West Cap Corp (NYSE:PNW) was reduced too.

Investors sentiment increased to 0.9 in Q2 2017. Its up 0.05, from 1.53 in 2017Q1. It increased, as 63 investors sold PG shares while 714 reduced holdings. 162.82 million shares or 0.84% more from 161.46 million shares in 2017Q1 were reported. 2 have given the stock a Hold rating, 0 as Underperform and 0 as Sell. Lowe Brockenbrough & reported 1.5% of its portfolio in Procter & Gamble Co (NYSE:PG). The value of the position overall is up by 2,550.0%. Morgan Stanley has 538,924 shares for 0% of their portfolio. Texas Permanent School Fund holds 59,334 shares or 0.07% of its portfolio. Middleton & Inc Ma has invested 0.49% in Procter & Gamble Co (NYSE:PG). 256,943 are held by Credit Suisse Ag. American International Group Inc now holds 96,335 shares with a value of $312,000. Federated Invsts Pa invested in 0.01% or 44,010 shares. State Of Tennessee Treasury Department accumulated 0.01% or 150,000 shares. Cubic Asset Mngmt Limited Liability Co invested in 11,845 shares. Wells Fargo & Mn has 596,273 shares. Tradewinds Cap Management Limited Liability reported 25 shares. The company had Year Ago Sales of 14.2 Million. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Therefore 43% are positive. Proctor & Gamble had 67 analyst reports since August 4, 2015 according to SRatingsIntel. Antares Pharma presently has a consensus rating of "Buy" and an average target price of $3.84. The rating was upgraded by Wood to "Outperform" on Thursday, July 27. The firm has "Buy" rating by H.C. Wainwright given on Wednesday, November 8. Jefferies has "Buy" rating and $3 target. The firm has "Sell" rating given on Wednesday, August 19 by Zacks. Jefferies maintained the shares of ATRS in report on Monday, August 7 with "Buy" rating. The firm has "Outperform" rating given on Monday, July 31 by Hovde Group.

Antares Pharma, Inc.is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. It now has negative earnings.

Investors sentiment decreased to 2.07 in Q2 2017.


Antares Pharma Cmn in recent headlines. 45 funds opened positions while 90 raised stakes. Antares Pharma Inc (NASDAQ:ATRS) has risen 207.14% since November 12, 2016 and is uptrending. Brown Advisory Securities Lc reported 275,000 shares stake.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, November 7th. KCG Holdings Inc. raised its stake in Antares Pharma by 48.8% in the 1st quarter. It is 0.00% or $0 reaching $0 per share. Avenir Corporation holds 351,685 shares or 0.1% of its portfolio. Atlantic Grp Inc Ltd reported 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS). Armistice Capital Llc who had been investing in Antares Pharma Inc for a number of months, seems to be less bullish one the $287.79 million market cap company. Metropolitan Life Insur Communications Ny accumulated 103,987 shares or 0% of the stock. Baystate Wealth Management Llc stated it has 1,397 shares. Planning has 0.01% invested in Antares Pharma Inc (NASDAQ:ATRS) for 58,233 shares. However the six-month change in the insider ownership was recorded -6.17%, as well as three-month change in the institutional ownership was recorded 0.09%. Citadel Advisors Ltd Limited Liability Company owns 130,892 shares. Alliancebernstein L.P. purchased a new position in shares of Antares Pharma during the second quarter worth about $119,000.

November 8 investment analysts at HC Wainwright made no change to the stock rating of "Buy" with a current price target of $3.50. Therefore 100% are positive. For the current year the company's revenue estimates are $54.73 Million compared to low analyst estimates of $49.35 Million and high estimates of $56.7 Million according to 5 number of analysts. The company was maintained on Wednesday, November 8 by H.C. Wainwright. Goldman Sachs downgraded the shares of PG in report on Monday, January 9 to "Sell" rating. The rating was maintained by Jefferies on Monday, August 7 with "Buy". HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Antares Pharma in a research note on Sunday, September 10th. UBS maintained it with "Neutral" rating and $81 target in Monday, October 26 report. The stock of Procter & Gamble Co (NYSE:PG) has "Buy" rating given on Tuesday, September 19 by Bank of America.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER